48,830
edits
Difference between revisions of "Urothelial carcinoma in situ"
Jump to navigation
Jump to search
Urothelial carcinoma in situ (view source)
Revision as of 14:07, 6 January 2014
, 14:07, 6 January 2014→IHC
m (→General) |
(→IHC) |
||
| Line 52: | Line 52: | ||
*Ki-67 ~50% of cells - deep and superficial. | *Ki-67 ~50% of cells - deep and superficial. | ||
**Normal ~10% of cells, confined to basal aspect. | **Normal ~10% of cells, confined to basal aspect. | ||
*CD44 -ve.<ref name=pmid24225842>{{Cite journal | last1 = Aron | first1 = M. | last2 = Luthringer | first2 = DJ. | last3 = McKenney | first3 = JK. | last4 = Hansel | first4 = DE. | last5 = Westfall | first5 = DE. | last6 = Parakh | first6 = R. | last7 = Mohanty | first7 = SK. | last8 = Balzer | first8 = B. | last9 = Amin | first9 = MB. | title = Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. | journal = Am J Surg Pathol | volume = 37 | issue = 12 | pages = 1815-23 | month = Dec | year = 2013 | doi = 10.1097/PAS.0000000000000114 | PMID = 24225842 }}</ref> | |||
**Positive in ''indeterminant'' and ''negative''. | |||
==Sign out== | ==Sign out== | ||